Clinical Trial

Study on the Safety and Efficacy of MR-Linac Technique in Patients With Unresectable Locally Advanced Colon Cancer

Study acronym: UNLACC
Recruiting
View on ClinicalTrials.gov →
Summary
In this phase I single-arm clinical study, 20 patients with T4 unresectable locally advanced colon cancer are proposed to be enrolled, who will be treated with MR-Linac with short course radiotherapy (25Gy/5F), followed by 4 cycles of mFOLFOX6 or 3 cycles of XELOX chemotherapy, then radical surgical resection, and then postoperatively with 8 cycles of mFOLFOX6 or 5 cycles of XELOX. The study will assess patients' surgical R0 resection rate, pCR or cCR rate, PFS, OS, and related adverse effects of treatment, aiming to explore the feasibility, safety, and efficacy of MR-Linac in the treatment of unresectable locally advanced colon cancer.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-02-02; most recent amendment 2025-09-02.
Status change: Not Yet Recruiting → Recruiting 2025-09-02
Trial Details
NCT Number NCT06244537
Lead Sponsor Sichuan Cancer Hospital and Research Institute
Conditions Safety and Efficacy
Enrollment 20 participants
Start Date 2024-04-01
Primary Completion 2027-12-30 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-09-09